MedTrace Logo

To Evaluate Clinical Outcome and Injection Compliance of Scilin

NCT01588639 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2683

Last updated 2015-01-13

No results posted yet for this study

Summary

This is a prospective, multi-center, open-label, non-interventional, 12-week study in people with type 2 diabetes mellitus who are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice. The term study insulins will be used in this protocol for these drugs and combinations.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin (Scilin N, BAY81-9924)

Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.

DRUG

Insulin (Scilin R _BAY81-9924

Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice

DRUG

Insulin(Scilin M30_BAY81-9924)

Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-10-31
Completion
2014-01-31

Countries

  • China

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01588639 on ClinicalTrials.gov